放射性核素氯化锶联合唑来膦酸应用于乳腺癌骨转移患者中的效果  

Effect of Radionuclide Strontium Chloride combined with Zoledronic Acid in Breast Cancer Patients with Bone Metastasis

作　　者：武健 WU Jian(Department of Nuclear Medicine,Shandong Health Care Group Zibo Hospital,Zibo 255120,China)

机构地区：[1]山东颐养健康集团淄博医院核医学科,山东淄博255120

出　　处：《中国药物经济学》2023年第12期38-40,44,共4页China Journal of Pharmaceutical Economics

摘　　要：目的 探讨放射性核素氯化锶联合唑来膦酸应用于乳腺癌骨转移治疗中的效果。方法 选取2018年2月至2022年2月山东颐养健康集团淄博医院收治的70例乳腺癌骨转移患者作为研究对象,按治疗方式不同分为试验组与对照组,各35例。对照组采用唑来膦酸,试验组在对照组基础上予以放射性核素氯化锶,比较两组患者疼痛情况、肿瘤标志物、骨代谢指标水平及不良反应发生情况。结果 治疗后及第1次随访时两组数字评分法(NRS)评分与癌胚抗原(CEA)、糖类抗原125(CA125)、骨吸收指标Ⅰ型胶原羧基端肽β特殊序列(β-CTX)以及骨形成标志物总Ⅰ型胶原氨基端延长肽(TPINP)水平降低(P<0.05),且试验组NRS评分与CEA、CA125、β-CTX以及TPINP水平低于对照组(P<0.05);试验组不良反应发生率(28.57%)与对照组的不良反应发生率(20.00%)比较差异无统计学意义(P>0.05)。结论 在对乳腺癌骨转移患者进行治疗时采取放射性核素氯化锶联合唑来膦酸治疗方案,可有效缓解疼痛,降低肿瘤标志物水平,延缓癌细胞转移,改善病情。Objective To explore the effect of radionuclide strontium chloride combined with zoledronic acid in the treatment of breast cancer with bone metastasis.Methods Seventy patients with bone metastasis of breast cancer admitted to Zibo Hospital of Shandong Nursing and Health Group from February 2018 to February 2022 were selected as the study objects,and were divided into experimental group and control group according to different treatment methods,with 35 cases in each group.The control group was given zoledronic acid,and the experimental group was given radionuclide strontium chloride on the basis of the control group.The pain status,tumor markers,bone metabolism indexes and the occurrence of adverse reactions were compared between the two groups.Results After treatment and at the first follow-up,NRS scores,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),bone resorption index type I collagen carboxy-terminal peptideβspecial sequence(β-CTX)and total type I collagen amino terminal prolongating peptide(TPINP)were decreased by in both groups(P<0.05).NRS score,CEA,CA125,β-CTX and TPINP levels in experimental groups were lower than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the experimental group(28.57%)and the control group(20.00%)(P>0.05).Conclusion Radionuclide strontium chloride combined with zoledronic acid can effectively relieve pain,reduce the level of tumor markers,delay cancer cell metastasis and improve the condition of breast cancer patients with bone metastasis.

关 键 词：放射性核素氯化锶 唑来膦酸 乳腺癌骨转移 疗效 

分 类 号：R737.9[医药卫生—肿瘤] R979.1[医药卫生—临床医学]